| Oct 30 |
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
|
| Oct 29 |
Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment
|
| Oct 29 |
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
|
| Aug 9 |
Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33
|
| Aug 9 |
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
|
| Jul 30 |
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
|
| Jul 10 |
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
|
| Jul 1 |
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
|
| Jun 25 |
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
|
| Jun 18 |
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
|
